A July 16 law-firm release said it is reviewing recent corporate actions at Venture Global, though a newer version names Kymera Therapeutics instead and seeks shareholder inquiries about rights and options.
Purcell & Lefkowitz LLP said on July 16, 2026 that it is investigating a company on behalf of shareholders to determine whether its directors breached fiduciary duties in connection with recent corporate actions. The older record identifies Venture Global, Inc. (NYSE: VG), while the newer record identifies Kymera Therapeutics, Inc. (NASDAQ: KYMR), indicating a discrepancy between versions of the announcement. In both versions, the firm invited shareholders seeking information about their rights and options to contact it through a case webpage, by email, or by phone, and described itself as representing shareholders in matters involving securities fraud, breaches of fiduciary duty, and other corporate misconduct.